前列腺癌患者因抑郁接受药物治疗与心血管疾病风险增加相关
研究基于荷兰癌症登记与PHARMO数据库,纳入5262例无心血管病史的1年前列腺癌幸存者,随访13年。经抑郁药物治疗者发生心血管疾病的风险较未治疗者升高51%(HR 1.51,95%CI 1.06-2.15),该风险在≤65岁、未接受放疗、接受激素治疗、未手术及III-IV期患者中显著。
要点
- 前列腺癌幸存者中抑郁药物治疗与心血管疾病风险独立相关。
- 年龄≤65岁者风险更高(HR 2.91,95%CI 1.52-5.55)。
- 临床决策前应关注抑郁状态并及时筛查心血管疾病。
核心结论
- 经抑郁药物治疗的前列腺癌幸存者发生心血管疾病的风险增加51%。
研究设计与样本
- 基于荷兰癌症登记和PHARMO数据库的注册队列研究,纳入1999-2011年诊断的5262例无心血管病史的1年前列腺癌幸存者。
主要发现
- 随访13年期间,327例(6%)发生心血管疾病。
- 全调整后,抑郁药物治疗者心血管疾病风险HR为1.51(95%CI 1.06-2.15)。
- 年龄≤65岁者HR为2.91(95%CI 1.52-5.55)。
- 未接受放疗者HR为1.63(95%CI 1.01-2.65),接受激素治疗者HR为1.76(95%CI 1.09-2.85)。
- 未手术者HR为1.55(95%CI 1.07-2.25),III期HR为2.21(95%CI 1.03-4.74),IV期HR为2.47(95%CI 1.03-5.89)。
临床怎么用
- 在前列腺癌治疗决策前应关注抑郁状态,并注意心血管疾病的及时筛查与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the associations between pharmaceutically treated anxiety and depression and incident cardiovascular disease (CVD) among 1-year prostate cancer survivors. PATIENTS AND METHODS: A registry-based cohort study design was used to describe the risk of incident CVD in adult 1-year prostate cancer survivors without a history of CVD. Patients with prostate cancer diagnosed between 1999 and 2011 were selected from the Netherlands Cancer Registry. Drug dispenses were retrieved from the PHARMO Database Network and were used as proxy for CVD, anxiety, and depression. Data were analysed using Cox regression analysis to examine the risk associations between pharmaceutically treated anxiety and depression entered as a time-varying predictor with incident CVD in 1-year prostate cancer survivors, while controlling for age, traditional CVD risk factors, and clinical characteristics. RESULTS: Of the 5262 prostate cancer survivors, 327 (6%) developed CVD during the 13-year follow-up period. Prostate cancer survivors who were pharmaceutically treated for depression had an increased risk of incident CVD after full adjustment compared to prostate cancer survivors who were not pharmaceutically treated for depression (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.06-2.15). The increased risk of incident CVD amongst those pharmaceutically treated for depression compared to those who were not pharmaceutically treated for depression, was only valid among: prostate cancer survivors who were aged ≤65 years (HR 2.91; 95% CI 1.52-5.55); those who were not treated with radiotherapy (HR 1.63; 95% CI 1.01-2.65); those who were treated with hormones (HR 1.76; 95% CI 1.09-2.85); those who were not operated upon (HR 1.55; 95% CI 1.07-2.25); and those with tumour stage III (HR 2.21; 95% CI 1.03-4.74) and stage IV (HR 2.47; 95% CI 1.03-5.89). CONCLUSION: Patients with prostate cancer who were pharmaceutically treated for depression had a 51% increased risk of incident CVD after adjustment for anxiety, age, traditional CVD risk factors, and clinical characteristics. The results emphasise the need to pay attention to (pharmaceutically treated) depressed patients with prostate cancer prior to deciding on prostate cancer treatment and for a timely detection and treatment of CVD.
引用
- Wollersheim BM, Boekhout AH, van der Poel HG, et al. The risk of developing cardiovascular disease is increased for patients with prostate cancer who are pharmaceutically treated for depression. BJU Int. 2019. PMID: 31773851. doi:10.1111/bju.14961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。